Ketamine Therapy for Chronic Pain: Clinical Decision-Making for Providers
A clinician's guide to ketamine therapy for chronic pain—covering NMDA mechanisms, evidence-based outcomes, contraindications, and patient selection criteria for referral decisions.A clinician's guide to ketamine therapy for chronic pain—covering NMDA mechanisms, evidence-based outcomes, contraindications, and patient selection criteria for referral decisions.
Jan 13
/
Peter H Addy
As a licensed therapist specializing in psychedelic-affirming approaches to chronic pain, I regularly support clinicians making referral decisions about ketamine therapy. For patients who have exhausted conventional treatment — and for the providers working alongside them — understanding what ketamine does and doesn't offer is essential for sound clinical decision-making.
This is not a post for patients deciding whether to pursue ketamine therapy. It's for clinicians weighing whether and how to incorporate ketamine therapy into referral pathways for chronic pain populations.
For the mechanisms and clinical applications of KAP, see Ketamine-Assisted Psychotherapy for Chronic Pain: Evidence, Mechanisms, and Patient Selection. For integration techniques that support lasting outcomes, see Beyond the Session: Psychedelic Integration Practices for Chronic Pain Treatment.
Understanding Ketamine's Pharmacological Mechanism in Pain
Ketamine works primarily by inhibiting the brain's NMDA receptors, disrupting the pain signaling pathways that perpetuate chronic pain cycles while simultaneously promoting neuroplasticity. It produces meaningful analgesia, particularly for neuropathic pain states, and has demonstrated promise for complex regional pain syndrome (CRPS), fibromyalgia, and some cases of chronic low back pain.
What distinguishes ketamine-assisted psychotherapy (KAP) from standard ketamine infusion protocols is the integration of psychotherapeutic support before, during, and after ketamine administration. Where infusion-only approaches leave the patient unattended during the experience, KAP maintains active therapeutic presence throughout the process. This combined approach appears to extend and deepen benefits beyond what pharmacology alone achieves.
Evidence-Based Benefits: What the Research Supports
Research supports ketamine's efficacy for treatment-resistant pain conditions. A 2022 meta-analysis demonstrated that intravenous ketamine significantly reduced pain scores compared to control interventions, with effects persisting in some patients for weeks following treatment. Additional systematic reviews have examined the analgesic effects across specific pain populations. Pharmacokinetic research has provided further grounding for understanding ketamine's clinical profile.
Beyond analgesia, ketamine carries particular relevance for chronic pain populations because of its rapid antidepressant effects — clinically meaningful within hours in many patients. Depression and chronic pain frequently co-occur and share neurobiological pathways, making this dual-action relevant to treatment planning.
For patients with opioid dependence — common in chronic pain management — ketamine represents a potentially meaningful alternative pathway. Some studies suggest it may reduce opioid requirements while providing adequate pain control, though this area requires more research before firm clinical conclusions can be drawn. More recent research continues to examine these mechanisms.
Understanding the Risks and Clinical Limitations
Ketamine is not appropriate for all patients, and the consequences of poor candidate selection are significant enough to warrant careful protocol development.
Common side effects at therapeutic doses include psychedelic symptoms (dissociation, perceptual changes, and in some cases brief panic), nausea, somnolence, and cardiovascular stimulation — typically mild to moderate and transient, but requiring monitoring.
Key contraindications include:
- Personal or family history of psychosis or schizophrenia spectrum disorders (ketamine may reactivate or worsen symptoms)
- Severe cardiovascular conditions
- Elevated intracranial pressure
- Active or recent substance abuse disorders, with particular attention to dissociative substance misuse
The regulatory and payer landscape presents additional clinical-context considerations. Insurance rarely covers ketamine for pain management, creating access barriers that affect treatment completion and follow-through. The growth of commercial ketamine clinic models has also raised concerns about inadequate screening and follow-up protocols in some settings — making clinicians' referral decisions all the more important.
Patient Selection: Clinical Criteria for Referral Consideration
Professional clinical guidelines generally suggest ketamine should be considered after the failure of standard treatments, including adequate trials of appropriate pharmacological and non-pharmacological approaches.
A sound pre-referral evaluation should assess:
- Medical history: Cardiovascular health, current medications and potential interactions, seizure history
- Psychiatric conditions: Psychosis risk, mood disorders, trauma history, current psychiatric stability
- Substance use: Current and historical use patterns, misuse of dissociatives or other substances
- Treatment expectations: Realistic understanding of what ketamine can and cannot offer, and willingness to engage in integration support
The KAP Medical Assessment and KAP Psychological Assessment courses provide structured frameworks for conducting this evaluation process competently, whether you're working directly in KAP or making informed referrals to collaborating providers.
Ideally, candidate evaluation involves an interdisciplinary team: pain specialist, prescribing medical provider, and mental health professional. The therapist's role in this team extends beyond clinical screening into ongoing preparation and integration support.
Integration: The Therapeutic Dimension That Determines Outcomes
The evidence is consistent: ketamine plus skilled psychotherapeutic integration outperforms ketamine alone. The neuroplastic window opened by ketamine treatment creates conditions for meaningful therapeutic change — but only when that window is used intentionally.
Effective integration involves preparation sessions before treatment, therapeutic support during the experience where appropriate, and structured integration therapy afterward. This framework helps patients process insights, implement behavioral changes, and develop cognitive and somatic strategies that extend the neuroplastic opportunity created by the medication.
For clinicians seeking to develop clinical competence in this area, the Comprehensive KAP Assessment Bundle provides structured training across the full spectrum of KAP clinical assessment — medical screening, psychological evaluation, and suicide risk assessment — so that providers can participate competently in the collaborative care model this treatment demands.
Ketamine therapy represents neither a miracle nor a last resort. For carefully selected chronic pain patients who haven't responded to conventional approaches, it is a potentially valuable tool — and for the clinicians who work with these patients, developing the assessment and integration skills to support it well is increasingly part of competent, contemporary practice.
